Medtech stocks are set to end 2025 on a mixed note, with shares of Becton Dickinson (BDX.N) , Zimmer Biomet (ZBH.N) , Baxter (BAX.N) and Stryker (SYK.N) headed for yearly losses
Boston Scientific (BSX.N) , Medtronic (MDT.N) , Johnson &amp; Johnson (JNJ.N) , Abbott (ABT.N) , Edwards Lifesciences (EW.N) and GE HealthCare (GEHC.O) , however, are on track to finish the year in positive territory
Zimmer Biomet shares are down 14.1% this year amid repeated profit warnings and are bracing for a third consecutive loss, while Baxter has shed about 33.8% in 2025 and faces a fourth straight year in the red due to continued pain from profit warnings and hurricane disruptions at its key facility
Edwards Lifesciences, Boston Scientific, and Abbott shares are set to end 2025 up over 16%, 7%, and 11%, respectively. BSX and EW posted standout gains on repeated profit upgrades and strong revenue from top heart devices
JNJ investors rewarded consistent beats, with the stock climbing over 43%, hitting a record high, outpacing the medtech sector and snapping a two-year losing streak
“We see hope for a more peaceful ‘26 for MedTech. With tariffs mitigated and policy risks manageable, we expect robust MedTech growth and remain constructive,” said Jefferies analysts in a note two weeks ago
MedTech stocks performance in 2025
<img src="https://imageproxy.pbkrs.com/https://reut.rs/49yXzyn?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1420" height="1100" original-src="https://imageproxy.pbkrs.com/https://reut.rs/49yXzyn"/>

GEHC

Medtech stocks are ending 2025 with a clear divide: Becton Dickinson, Zimmer Biomet, Baxter, and Stryker are facing yearly losses, while Boston Scientific, Medtronic, Johnson & Johnson, Abbott, Edwards Lifesciences, and GE HealthCare are on track for gains. Zimmer Biomet and Baxter have seen significant declines due to profit warnings and disruptions. In contrast, JNJ has surged over 43%, reaching a record high. Analysts predict a more stable 2026 for MedTech, anticipating strong growth as tariffs and policy risks ease.

BUZZ-Medtech: Clear split between gainers and losers in 2025